Abstract: ［Abstract］ Objective〖HTSS〗To evaluate the clinical value of the combination regimen of retitroxel and lobaplatin in transcatheter arterial chemoembolization(TACE) for patients with primary hepatocellular carcinoma(PHC).
  〖WTHZ〗Methods〖HTSS〗Patients with primary liver cancer who received TACE treatment were divided into two groups: observation group(n=53) and control group(n=50), which received TACE treatment combined with Rigtroxel and Loplatin. The efficacy was evaluated by Modified Response Evaluation Criteria in Solid Tumors standard 4 weeks after operation. The last follow-up period was October 30, 2018.
  〖WTHZ〗Results〖HTSS〗The median progression-free survival(mPFS) was 14.8 months in the treatment group and 11.2 months in the control group, with significant difference(P＜0.05). The median overall survival time was 23.7 months and 21.6 months, respectively, with no significant difference(P＞0.05). The disease effective rate(ORR) was 47.1% and 46.0%, respectively, with no significant difference(P>0.05). The disease control rate(DCR) was 88.7% and 62.0%, respectively, with significant difference(P＜0.05).
  〖WTHZ〗Conclusion〖HTSS〗Retitroxel combined with Loplatin is a valuable perfusion chemotherapy regimen in TACE treatment, which deserves further discussion.

Key words: liver neoplaasms, retitraxel； loplatin； transcatheter arterial chemoembolization